Efficacy and safety of oral beclomethasone dipropionate for ileal or ileal-right colon Crohn's disease of mild-to-moderate activity or in remission: Retrospective study

摘要: Although conventional glucocorticosteroids are the main treatments for active Crohn's disease, several problems associated with steroid dependence and steroid-related adverse events. To assess efficacy safety of oral beclomethasone dipropionate (BDP) coated tablets in adults mild-to-moderate disease. Thirty-four patients (age 18-70years) a diagnosis disease confirmed by criteria (barium enema, clinical criteria, colonoscopy, histology) were retrospectively evaluated study. All subjects received treatment schedule BDP 5-10mg/day 24weeks. significantly (p=0.005) reduced mean Disease Activity Index (CDAI) score from 169.6 at baseline to 123.2 after Clinical success was evident 24weeks 66.7% initial remission maintained week 24 93.8% baseline. Overall, female non-smokers had best response treatment. well tolerated only events observed nausea (n=1), facial erythema (n=1) one patient raised fasting blood glucose level. These results clearly suggest that effective safe ileal or ileal-right colonic localisation.